bluebird bio has applied to the SEC for a tax-free spin-off of its oncology business into a separate public company, 2seventy bio. bluebird plans to distribute shares of 2seventy bio to its shareholders on a 3:1 basis. The spin-off is scheduled to be completed by early November 2021.